{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Cancers&page=47",
    "query": {
      "condition": "Multiple Cancers",
      "page": 47
    },
    "page_size": 10
  },
  "pagination": {
    "page": 47,
    "page_size": 10,
    "total_count": 4777,
    "total_pages": 478,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Cancers&page=48&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Cancers&page=46&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T17:46:09.545Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05972135",
      "title": "Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Teclistamab",
          "type": "DRUG"
        },
        {
          "name": "Talquetamab",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "Oral Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SCRI Development Innovations, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2023-10-23",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2026-04-22",
      "last_synced_at": "2026-10-31T17:46:09.545Z",
      "location_count": 17,
      "location_summary": "Tucson, Arizona • Denver, Colorado • Newark, Delaware + 12 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05972135"
    },
    {
      "nct_id": "NCT03524235",
      "title": "Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma",
        "CLL",
        "Chronic Lymphocytic Leukemia",
        "Lymphoma",
        "Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Total Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Haploidentical Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "CD56-Enriched Donor Lymphocyte Infusion",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bendamustine",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "PROCEDURE",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Noah Merin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 20,
      "start_date": "2018-07-18",
      "completion_date": "2024-11-06",
      "has_results": false,
      "last_update_posted_date": "2024-11-12",
      "last_synced_at": "2026-10-31T17:46:09.545Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03524235"
    },
    {
      "nct_id": "NCT02139774",
      "title": "Using Walk With Ease Walking Program With Men 65 and Older Being Treated for Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Walk with Ease",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "65 Years and older · Male only"
      },
      "enrollment_count": 15,
      "start_date": "2013-10",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2015-12-04",
      "last_synced_at": "2026-10-31T17:46:09.545Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02139774"
    },
    {
      "nct_id": "NCT07280897",
      "title": "SCIPI Implementation and Evaluation: A Multi-site Proof-of-Concept Pilot Trial",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "SCIPI",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2026-10-01",
      "completion_date": "2029-09-29",
      "has_results": false,
      "last_update_posted_date": "2025-12-19",
      "last_synced_at": "2026-10-31T17:46:09.545Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07280897"
    },
    {
      "nct_id": "NCT01155713",
      "title": "Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasm",
        "Cancer",
        "Tumors"
      ],
      "interventions": [
        {
          "name": "TKI258",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2010-07",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2020-12-21",
      "last_synced_at": "2026-10-31T17:46:09.545Z",
      "location_count": 4,
      "location_summary": "Scottsdale, Arizona • Durham, North Carolina • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01155713"
    },
    {
      "nct_id": "NCT01596647",
      "title": "Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors, Excluding Breast Cancer"
      ],
      "interventions": [
        {
          "name": "caffeine",
          "type": "DRUG"
        },
        {
          "name": "diclofenac",
          "type": "DRUG"
        },
        {
          "name": "omeprazole",
          "type": "DRUG"
        },
        {
          "name": "midazolam",
          "type": "DRUG"
        },
        {
          "name": "TKI258",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2012-05",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2020-12-21",
      "last_synced_at": "2026-10-31T17:46:09.545Z",
      "location_count": 5,
      "location_summary": "Kansas City, Kansas • Detroit, Michigan • Minneapolis, Minnesota + 2 more",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01596647"
    },
    {
      "nct_id": "NCT02574455",
      "title": "Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Sacituzumab govitecan",
          "type": "DRUG"
        },
        {
          "name": "Eribulin",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Vinorelbine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 529,
      "start_date": "2017-11-07",
      "completion_date": "2020-12-08",
      "has_results": true,
      "last_update_posted_date": "2022-06-15",
      "last_synced_at": "2026-10-31T17:46:09.545Z",
      "location_count": 185,
      "location_summary": "Daphne, Alabama • Mobile, Alabama • Phoenix, Arizona + 144 more",
      "locations": [
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02574455"
    },
    {
      "nct_id": "NCT01603979",
      "title": "A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "AV-203",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AVEO Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2012-05",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2015-04-08",
      "last_synced_at": "2026-10-31T17:46:09.545Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Atlanta, Georgia • San Antonio, Texas",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01603979"
    },
    {
      "nct_id": "NCT00620594",
      "title": "A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Advanced Solid Tumors",
        "Cowden Syndrome"
      ],
      "interventions": [
        {
          "name": "BEZ235",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 183,
      "start_date": "2006-12-21",
      "completion_date": "2013-01-08",
      "has_results": false,
      "last_update_posted_date": "2020-12-09",
      "last_synced_at": "2026-10-31T17:46:09.545Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Greenville",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00620594"
    },
    {
      "nct_id": "NCT06449222",
      "title": "Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Breast Cancer",
        "Triple Negative Breast Cancer",
        "Metastatic Triple Negative Breast Cancers"
      ],
      "interventions": [
        {
          "name": "BNT327 Dose Level 1 (DL1)",
          "type": "DRUG"
        },
        {
          "name": "BNT327 Dose Level 1 (DL2)",
          "type": "DRUG"
        },
        {
          "name": "Nab-placlitaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Eribulin",
          "type": "DRUG"
        },
        {
          "name": "BNT327 Optimized Dose",
          "type": "DRUG"
        },
        {
          "name": "BNT327 Equivalent Q3W Dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioNTech SE",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 83,
      "start_date": "2024-08-26",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-10-31T17:46:09.545Z",
      "location_count": 13,
      "location_summary": "Beverly Hills, California • Los Angeles, California • Palo Alto, California + 10 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06449222"
    }
  ]
}